

**LEGISLATIVE FISCAL OFFICE**  
**Fiscal Note**



Fiscal Note On: **HB 526** HLS 19RS 713

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

<b>Date:</b> May 27, 2019 6:59 AM	<b>Author:</b> HOFFMANN
<b>Dept./Agy.:</b> LA Dept. of Health	<b>Analyst:</b> Zachary Rau
<b>Subject:</b> Opioid Use Disorder Treatments for Medicaid	

HEALTH/BEHAVIORAL RE DECREASE SG RV See Note Page 1 of 1  
Prohibits the imposition of prior authorization requirements in Medicaid managed care for certain prescription medications used in treating opioid use disorder

Proposed law prohibits Medicaid and Medicaid managed care organizations from restricting the prescription of opioid use disorder medication by prescriber type specialty for United States Food and Drug Administration-approved (FDA) treatments for opioid use disorder. Proposed law prohibits step therapy requirements prior to authorization of coverage by Medicaid and Medicaid managed care organizations for an FDA approved medication for treatment of opioid use disorder. Proposed law requires the listing of at least two formulations of buprenorphine/naloxone on the LA Medicaid fee-for-service drug list. Proposed law prohibits excluding coverage of prescriptions by Medicaid and Medicaid managed care organizations that are based upon court order.

<b>EXPENDITURES</b>	<b>2019-20</b>	<b>2020-21</b>	<b>2021-22</b>	<b>2022-23</b>	<b>2023-24</b>	<b>5 -YEAR TOTAL</b>
State Gen. Fd.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Agy. Self-Gen.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Local Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
<b>Annual Total</b>						

  

<b>REVENUES</b>	<b>2019-20</b>	<b>2020-21</b>	<b>2021-22</b>	<b>2022-23</b>	<b>2023-24</b>	<b>5 -YEAR TOTAL</b>
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Agy. Self-Gen.	DECREASE	DECREASE	DECREASE	DECREASE	DECREASE	
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Local Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
<b>Annual Total</b>						

**EXPENDITURE EXPLANATION**

Proposed law will reduce rebates associated with prescription of drugs on the Preferred Drug List by an estimated \$305,000 in FY 20 and \$333,000 in subsequent fiscal years for the LA Dept. of Health (see Revenue Explanation). LDH classifies these rebates as expenditure offsets. To the extent these reduced rebates affect expenditures for the department, LDH may require an appropriation from another source or absorb these expenditures by utilizing other available means of finance or reducing expenditures.

**REVENUE EXPLANATION**

The LA Dept. of Health (LDH) anticipates that proposed law would result in loss of \$305,000 in SGR collections in FY 20 and \$333,000 in subsequent fiscal years derived from reduced state supplemental rebates associated with opiate dependence treatments currently on the preferred drug list (PDL) realizing a reduced market share. For reference, LDH typically receives rebates from suppliers of drugs on the PDL as a result of their drugs' preferred status. The department reports that the scope of the state rebate loss is dependent upon decreased utilization of currently-preferred drugs and increased utilization of non-PDL drugs that would be placed on the PDL as a result of proposed law. LDH classifies these rebates as expenditure offsets.

Senate Dual Referral Rules  
 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}  
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House  
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}  
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

*Evan Brasseaux*  
**Evan Brasseaux**  
**Staff Director**